- Home
- AQST vs SLDB Comparison
AQST vs SLDB Comparison
Compare AQST & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- SLDB
- Stock Information
- Founded
- AQST 2004
- SLDB 2013
- Country
- AQST United States
- SLDB United States
- Employees
- AQST N/A
- SLDB N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AQST Health Care
- SLDB Health Care
- Exchange
- AQST Nasdaq
- SLDB Nasdaq
- Market Cap
- AQST 272.9M
- SLDB 234.8M
- IPO Year
- AQST 2018
- SLDB 2018
- Fundamental
- Price
- AQST $2.71
- SLDB $3.21
- Analyst Decision
- AQST Strong Buy
- SLDB Strong Buy
- Analyst Count
- AQST 5
- SLDB 10
- Target Price
- AQST $11.40
- SLDB $14.90
- AVG Volume (30 Days)
- AQST 1.7M
- SLDB 1.9M
- Earning Date
- AQST 05-12-2025
- SLDB 05-15-2025
- Dividend Yield
- AQST N/A
- SLDB N/A
- EPS Growth
- AQST N/A
- SLDB N/A
- EPS
- AQST N/A
- SLDB N/A
- Revenue
- AQST $54,228,000.00
- SLDB N/A
- Revenue This Year
- AQST N/A
- SLDB N/A
- Revenue Next Year
- AQST $40.62
- SLDB N/A
- P/E Ratio
- AQST N/A
- SLDB N/A
- Revenue Growth
- AQST 5.29
- SLDB N/A
- 52 Week Low
- AQST $2.12
- SLDB $2.41
- 52 Week High
- AQST $5.80
- SLDB $10.37
- Technical
- Relative Strength Index (RSI)
- AQST 54.01
- SLDB 52.03
- Support Level
- AQST $2.22
- SLDB $2.68
- Resistance Level
- AQST $2.79
- SLDB $3.32
- Average True Range (ATR)
- AQST 0.19
- SLDB 0.25
- MACD
- AQST 0.04
- SLDB 0.08
- Stochastic Oscillator
- AQST 75.64
- SLDB 87.91
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.